Longevity Medicine
Longevity Medicine: Understanding Ageing & Extending Healthspan
Professor Patrick Treacy is an Irish physician, author and international medical educator with a medical career spanning more than three decades. Longevity medicine and the biology of human ageing are areas of clinical, scientific and educational interest, alongside his work in dermatology, aesthetic and regenerative medicine.
His work in aesthetic medicine began in 1998. Drawing on his wider medical experience, he explores how chronic inflammation, mitochondrial dysfunction, cellular senescence, altered intercellular communication and declining regenerative capacity contribute to age-related disease and tissue dysfunction.
His approach to longevity medicine centres on a fundamental principle: ageing is not simply the passage of time, but a complex interaction of biological processes that may, to varying degrees, be measured, influenced and modified. Whether an intervention improves human healthspan requires evidence from appropriate human clinical studies.
His clinical and educational interests include GLP-1 receptor agonists, rapamycin, senolytics, NAD⁺, peptides and regenerative therapies. He distinguishes established human clinical benefits for specific indications from preclinical findings, biomarker changes, experimental interventions and unproven claims of extending human lifespan.
Through international lectures, medical education and published books, Professor Patrick Treacy advocates a philosophy of biological honesty — prioritising demonstrable improvements in tissue function, clinical outcomes and human healthspan over commercial promises of reversing ageing.
Understanding the Biological Pathways of Ageing
Ageing involves interconnected biological processes, including genomic instability, epigenetic changes, mitochondrial dysfunction, chronic inflammation, cellular senescence and declining regenerative capacity. These processes provide a framework for understanding changes in cellular function and tissue resilience over time.
Professor Patrick Treacy’s interests centre on how these pathways interact, how they relate to tissue repair and disease, and how emerging interventions should be evaluated. Understanding a biological mechanism does not, by itself, establish that targeting it will extend human life or improve healthspan.
Inflammaging and Chronic Disease
Inflammaging describes persistent low-grade inflammation associated with ageing. It offers a framework for examining the relationships between inflammatory signalling, metabolic dysfunction, tissue damage and age-related disease.
Professor Patrick Treacy explores these themes through his writing and medical education, including his published book The Fire That Won’t Go Out. His emphasis is on distinguishing mechanistic explanations from evidence that an intervention produces meaningful clinical benefit.
Regenerative Medicine and Tissue Repair
Professor Patrick Treacy’s clinical experience and interests encompass platelet-rich plasma (PRP), growth factors, regenerative signalling, photobiomodulation and tissue repair. An early adopter of PRP in aesthetic practice from 2003, he has also contributed to international education in regenerative medicine and aesthetic patient safety.
A central distinction in this work is between biostimulation and genuine regeneration. Stimulating a biological response, improving appearance or observing a laboratory marker should not automatically be described as restoring the structure and function of damaged tissue. Claims must be assessed against the intervention, clinical context and available human evidence.
His patient-safety work includes developing and teaching protocols for managing vascular complications following injectable treatments, with an emphasis on early recognition and responsible clinical practice.
The Longevity Ladder: Evidence Before Hype
The Longevity Ladder is a book project examining the evidence supporting contemporary interventions and the distinction between scientific promise and demonstrated clinical benefit.
Its scope includes GLP-1 therapies, rapamycin, senolytics, metformin, NAD⁺ and peptides. Each requires separate assessment: evidence for a particular disease indication cannot automatically be extended to a claim of slowing ageing or increasing lifespan in otherwise healthy people.
The project asks what evidence comes from laboratory or animal studies, what has been evaluated in humans, which outcomes were measured, and whether benefits outweigh risks in the population being considered. It distinguishes changes in biomarkers from improvements in function, disease outcomes and healthspan.
This discussion is educational, not a treatment protocol or an endorsement of self-medication. Experimental longevity claims require rigorous evaluation, and individual treatment decisions require appropriate clinical assessment.
International Longevity Medicine
Professor Patrick Treacy’s international involvement includes participation in the TimePie Longevity Forum, Shanghai, China, in 2026, and the IASRM World Regenerative Medicine Congress, New Delhi, India, in 2026.
He is also contributing to the development of a proposed longevity medicine session for IMCAS World 2027 in Paris, France. The proposed themes include biological pathways of ageing, chronic inflammation, regenerative interventions and the distinction between biological-age biomarkers and meaningful improvements in human healthspan. The session remains proposed and is not presented here as a confirmed programme appointment.
Professor Patrick Treacy receiving The Regenerative Innovator Award at the Longevity Revolution Awards 2026, during the 11th IASRM World Congress, New Delhi, India.
Longevity Books and Publications
Professor Patrick Treacy’s published books reflect his growing focus on ageing biology, chronic inflammation and regenerative medicine.
The Pathways of Ageing
Published, available on Amazon.
Professor Patrick Treacy presents a framework for understanding why we age and what modern medicine can realistically do about it. Drawing on his medical experience and interests in regenerative and longevity medicine, the book explores genomic stability and instability, epigenetic regulation and alterations, mitochondrial function and dysfunction, chronic inflammation, stem-cell regeneration and declining regenerative capacity.
Introducing the Treacy Model of Interconnecting Ageing Pathways, it challenges the search for a single cause of ageing and argues for a systems-based understanding of biological decline. Rather than focusing on isolated interventions, it examines the interconnected systems that shape lifespan, healthspan and human resilience.
The Fire That Won’t Go Out
A Physician’s Case for Biological Honesty About Chronic Inflammation
Published, available on Amazon.
Inflammation is not inherently the enemy: it is a protective response designed to act quickly, protect damaged tissue and then switch itself off. Professor Patrick Treacy examines what happens when that response persists, exploring chronic low-grade inflammation, inflammaging and their relationships with ageing, tissue dysfunction, metabolic disease, cardiovascular disease, autoimmune disorders, cancer, brain conditions and declining healthspan.
Drawing on clinical experience and developments in immunology, regenerative medicine, cellular biology and longevity science, the book considers immune dysregulation and why the solution is rarely as simple as suppressing inflammation altogether. It examines conventional anti-inflammatory drugs alongside NLRP3 inhibition and low-dose interleukin-2, distinguishing established treatments from investigational therapies.
Through the “Goldilocks window”, it explores why even an appropriate intervention can fail when delivered at the wrong biological moment, with the wrong intensity or to the wrong target.
The Longevity Ladder
What I prescribe, what I don't, and why the evidence matters.
Book project — publication pending.
A book project exploring evidence-based longevity interventions, separating established clinical benefits from experimental approaches and unsupported claims. It examines contemporary interventions and the distinction between scientific promise and demonstrated clinical benefit.